Terlipressin
- Generic Name
- Terlipressin
- Brand Names
- Terlivaz
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 14636-12-5
- Unique Ingredient Identifier
- 7Z5X49W53P
- Background
Terlipressin is a synthetic analogue of vasopressin, which is an endogenous neurohormone that acts as a vasoconstrictor. It is a prodrug of lypressin, or lysine vasopressin. Compared to endogenous vasopressin, terlipressin has a longer half life and increased selectivity for the V1 receptor. As a potent vasopressor, terlipressin has been investigated in vari...
- Indication
Terlipressin is a vasopressin receptor agonist indicated to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function. The US prescribing information states that patients with a serum creatinine > 5 mg/dL are unlikely to experience benefit from terlipressin.
- Associated Conditions
- Hepato-Renal Syndrome, Hepatorenal Syndrome Type 1, Oesophageal varices haemorrhage, Portal Hypertension
- Associated Therapies
- -
Perioperative Evaluation of Terlipressin Infusion During Living Donor Liver Transplantation on Incidence of Acute Kidney
- Conditions
- Interventions
- First Posted Date
- 2014-02-11
- Last Posted Date
- 2016-12-15
- Lead Sponsor
- National Liver Institute, Egypt
- Target Recruit Count
- 25
- Registration Number
- NCT02059460
- Locations
- 🇪🇬
National Liver Institute, Shebeen Alkom, Menoufiya, Egypt
Terlipressin Administration in Patients Undergoing Major Liver Resection
- First Posted Date
- 2013-08-14
- Last Posted Date
- 2018-03-29
- Lead Sponsor
- Insel Gruppe AG, University Hospital Bern
- Target Recruit Count
- 150
- Registration Number
- NCT01921985
- Locations
- 🇨🇭
Dep. of Visceral Surgery, University Hospital Berne, Berne, Switzerland
Efficacy and Safety of Monotherapy With Noradrenaline and Terlipressin in Patients of Cirrhosis With Septic Shock Admitted to Intensive Care Unit
- Conditions
- Interventions
- First Posted Date
- 2013-04-19
- Last Posted Date
- 2016-11-22
- Lead Sponsor
- Institute of Liver and Biliary Sciences, India
- Target Recruit Count
- 84
- Registration Number
- NCT01836224
- Locations
- 🇮🇳
Institute of liver and Biliary Sciences, New Delhi, Delhi, India
Continuos Terlipressin Infusion in Septic Shock
- First Posted Date
- 2012-10-02
- Last Posted Date
- 2014-12-30
- Target Recruit Count
- 1000
- Registration Number
- NCT01697410
- Locations
- 🇨🇳
Surgical intensive care unit, 1st affiliated hospital of Sun Yat-sen university, Guangzhou, Guangdong, China
An Exploratory Haemodynamic Study in Patients With Compensated Cirrhosis and Portal Hypertension
- Conditions
- Interventions
- First Posted Date
- 2012-07-16
- Last Posted Date
- 2016-03-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 47
- Registration Number
- NCT01640964
- Locations
- 🇬🇧
Novartis Investigative Site, Edinburgh, United Kingdom
TYPE 2 HEPATORENAL SYNDROME
- Conditions
- Interventions
- First Posted Date
- 2012-07-11
- Last Posted Date
- 2012-07-11
- Target Recruit Count
- 46
- Registration Number
- NCT01637454
- Locations
- 🇮🇳
Postgraduate Institute of Medical Education and Research Chandigarh, Chandigarh, India
A Study of Terlipressin in Patients With Hepatorenal Syndrome Type 1
- First Posted Date
- 2011-06-15
- Last Posted Date
- 2012-02-14
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 8
- Registration Number
- NCT01373606
- Locations
- 🇯🇵
Investigational site, Kanto, Japan
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
- First Posted Date
- 2010-06-14
- Last Posted Date
- 2022-11-29
- Lead Sponsor
- Mallinckrodt
- Target Recruit Count
- 196
- Registration Number
- NCT01143246
- Locations
- 🇺🇸
Scripps Clinic, La Jolla, California, United States
🇺🇸University of Kentucky Chandler Medical Center, Lexington, Kentucky, United States
🇺🇸Iowa City VA Health Care System, Iowa City, Iowa, United States
Terlipressin in Cirrhotic Patients With Recidivation Ascites Treated With Paracentesis and Albumin
- First Posted Date
- 2009-09-30
- Last Posted Date
- 2015-06-15
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 82
- Registration Number
- NCT00986817
- Locations
- 🇫🇷
CARBONELL Nicolas, Paris, France
Comparison of Terlipressin, Somatostatin, and Octreotide for Control of Variceal Bleeding
- Conditions
- Interventions
- First Posted Date
- 2009-08-26
- Last Posted Date
- 2018-03-19
- Lead Sponsor
- Korea University
- Target Recruit Count
- 1034
- Registration Number
- NCT00966355
- Locations
- 🇰🇷
Korea University Anam Hospital, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.